Figure 3

Plot showing the performance metrics of the validation cohort. (A) Receiving operating characteristic curves or risk prediction models for CS prostate cancer, (B) TPR and FPR, (C) Net benefit (%), (D) Net reduction in false‐positives (%) of the three risk prediction models.